Scientific Advisory Board
Senior Vice President, Research
Co-founder of Saniona
Susan E. Bates
Department of Medicine, Division of Hematology/Oncology, Herbert Irving Comprehensive Cancer Center, New York
Director, Translational Cancer Medicine, Columbia University College of Physicians and Surgeons
Scandion Oncology has two promising compounds in the pipeline. SCO-101, our most advanced lead candidate, is in clinical Phase I and II studies and SCO-201 is in preclinical testing. We expect to deliver proof-of-concept with SCO-101 in 2022. Scandion Oncology is building a pipeline of drugs that can revert anti-cancer drug resistance through different mechanisms. The aim is to increasingly broaden the offering of medicines able to combat anti-cancer drug resistance.
Our first-in-class lead compound SCO-101 has been shown to enhance the effect of certain standard chemotherapies when given in combination. Scandion Oncology has two programs in clinical development with SCO-101. The most advanced program, CORIST, for the treatment of drug resistant metastatic colorectal cancer is in clinical Phase II studies. The second program, PANTAX, for the treatment of inoperable or metastatic pancreatic cancer is in clinical Phase Ib studies.
Detailed analyses suggest the market for Scandion Oncology’s products to be more than EUR 4 billion annually.
We believe our programs could be attractive for various pharmaceutical companies to combine with their anti-cancer treatments.